Churg-Strauss syndrome: Eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome, is a systemic vasculitis of small-to medium vessels, characterized by asthma, transient pulmonary infiltrates, and hypereosinophilia.
Polyarteritis with lung involvement [Churg-Strauss]/EGPA
DOID EFO Endpoint Browser PheWeb
M13_CHURGSTRAUSS
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
145 |
4. Check minimum number of eventsNone |
145 |
5. Include endpointsNone |
145 |
6. Filter based on genotype QC (FinnGen only) |
140 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M30
- Name in latin
- Polyarteritis nodosa cum manifestationibus pulmonalibus
Similar endpoints
↥List of similar endpoints to
Polyarteritis with lung involvement [Churg-Strauss]/EGPA
based on the number of shared cases.
Similar with more cases:
- Polyarteritis nodosa and related conditions
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 674 | 428 | 243 |
| Only index persons | 564 | 368 | 196 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 59.17 | 58.51 | 60.28 |
| Only index persons | 57.40 | 56.70 | 58.70 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 140 | 94 | 46 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | 53.48 | 52.43 | 55.64 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 145
- Matched controls
- 1450
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M30.1
ICD-10 Finland
Polyarteritis with lung involvement [Churg-Strauss]
+∞
206.4
144
*
L04AX01
ATC
azathioprine; systemic
36.1
69.5
47
19
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
15.2
63.4
95
161
J45.9
ICD-10 Finland
Asthma, unspecified
13.1
56.6
88
153
J45.1
ICD-10 Finland
Nonallergic asthma
15.5
53.5
57
58
R03DC03
ATC
montelukast; oral
10.9
47.4
77
137
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
11.0
43.9
62
92
H02AB06
ATC
prednisolone; systemic
23.6
41.5
134
494
D72.1
ICD-10 Finland
Eosinophilia
182.3
40.0
40
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
11.7
38.3
47
57
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
12.6
34.9
39
41
R03AK08
ATC
formoterol and beclometasone; inhalant
16.1
34.3
32
25
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
8.7
34.2
108
364
J45.0
ICD-10 Finland
Predominantly allergic asthma
9.7
33.2
47
68
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
10.3
32.5
43
57
R03AK06
ATC
salmeterol and fluticasone; inhalant
7.6
30.3
58
117
L04AX03
ATC
methotrexate; systemic
8.6
29.7
47
77
H02AB07
ATC
prednisone; oral
7.6
28.0
51
97
R03AC12
ATC
salmeterol; inhalant
11.9
26.8
30
31
UDH02
NOMESCO Finland
Rhinopharyngoscopy
9.0
25.9
37
53
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
10.7
25.5
31
36
M05BA04
ATC
alendronic acid; oral
8.4
25.4
39
61
J45
ICD-10 Finland
Asthma
7.7
24.1
40
68
R01AD08
ATC
fluticasone; nasal
5.4
23.0
82
282
R03BB04
ATC
tiotropium bromide; inhalant
7.8
22.8
37
61
R03BA05
ATC
fluticasone; inhalant
5.4
21.1
59
164
J33.0
ICD-10 Finland
Polyp of nasal cavity
23.8
20.5
29
15
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.4
19.8
106
487
R03BA08
ATC
ciclesonide; inhalant
7.0
19.8
35
63
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
8.4
19.4
28
40
R03AC02
ATC
salbutamol; inhalant
6.6
19.1
121
630
J32.4
ICD-10 Finland
Chronic pansinusitis
31.6
18.5
24
9
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
8.6
18.5
26
36
J82
ICD-10 Finland
Pulmonary eosinophilia, not elsewhere classified
+∞
18.1
17
*
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
17.9
18.0
28
19
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.4
18.0
35
69
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
8.7
18.0
25
34
R03BA02
ATC
budesonide; inhalant
4.7
17.8
59
185
UGC12
NOMESCO Finland
Flexible bronchoscopy
6.9
17.7
31
55
R50.9
ICD-10 Finland
Fever, unspecified
5.0
17.0
47
127
R03AK07
ATC
formoterol and budesonide; inhalant
4.5
16.8
60
198
J45.8
ICD-10 Finland
Mixed asthma
21.8
16.7
24
13
WZC30
NOMESCO Finland
Teaching
4.9
16.5
46
125
R03AC13
ATC
formoterol; inhalant
7.5
16.5
26
41
N30.1
ICD-10 Finland
Interstitial cystitis (chronic)
43.3
15.8
19
5
J01MA14
ATC
moxifloxacin; systemic
5.6
15.7
35
78
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
4.4
15.5
54
174
TDM10
NOMESCO Finland
Puncture of maxillary antrum
14.1
15.3
26
22
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
13.0
15.3
27
25
J33.8
ICD-10 Finland
Other polyp of sinus
21.3
15.2
22
12
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
5.8
15.1
32
68
ZX120
NOMESCO Finland
Intravenous
5.5
14.9
34
77
H02AB04
ATC
methylprednisolone; systemic
4.4
13.8
44
131
UDM02
NOMESCO Finland
Sinoscopy
29.1
13.7
18
7
Z01.8
ICD-10 Finland
Other specified special examinations
4.0
13.5
52
178
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.8
13.0
55
200
R03BA01
ATC
beclometasone; inhalant
4.3
13.0
42
126
M31.3
ICD-10 Finland
Wegener granulomatosis
+∞
12.7
12
*
XG474
NOMESCO Finland
Exhalation nntrogen oxide
12.7
12.5
22
20
R03AC03
ATC
terbutaline; inhalant
4.4
12.3
37
105
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.0
12.0
23
44
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
13.4
11.8
20
17
R03DA04
ATC
theophylline; systemic, rectal
9.4
11.7
24
30
297, ,
Kela drug reimbursment
+∞
11.6
11
*
M31.1
ICD-10 Finland
Thrombotic microangiopathy
+∞
11.6
11
*
DHB20
NOMESCO Finland
Polypectomy of internal nose
22.2
11.4
16
8
J01FA06
ATC
roxithromycin; oral
3.2
11.0
84
432
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.7
10.9
43
147
N02AX02
ATC
tramadol; systemic, rectal
3.2
10.9
88
467
KCV04
NOMESCO Finland
Distension of bladder with fluid
64.9
10.8
12
*
3028
Kela drug reimbursment
Mepolizumab
118.2
10.6
11
*
R03DX09
ATC
mepolizumab; parenteral
+∞
10.5
10
*
M30.0
ICD-10 Finland
Polyarteritis nodosa
+∞
10.5
10
*
TGC00
NOMESCO Finland
Bronchial lavation
11.3
10.4
19
19
A02BC01
ATC
omeprazole; systemic
3.2
10.3
61
268
L04AA06
ATC
mycophenolic acid; systemic
18.4
10.1
15
9
GX1L5
NOMESCO Finland
Exhaled nitric oxide analysis
21.9
10.0
14
7
R01AD01
ATC
beclometasone; nasal
3.6
9.9
39
133
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
4.8
9.8
24
57
XG410
NOMESCO Finland
Flow-volume spirometry
9.8
9.6
19
22
R96
ICPC
Asthma
4.6
9.5
25
63
M31.9
ICD-10 Finland
Necrotizing vasculopathy, unspecified
+∞
9.5
9
*
J46
ICD-10 Finland
Status asthmaticus
15.0
9.4
15
11
J01MA12
ATC
levofloxacin; systemic
3.4
9.3
42
156
A01AB09
ATC
miconazole; local oral
4.4
9.3
26
69
R01AD05
ATC
budesonide; nasal
4.6
9.2
24
60
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.1
9.2
51
214
GD1AD
NOMESCO Finland
Thorax CT examination
8.1
9.1
20
28
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
4.8
9.0
22
52
R06AE07
ATC
cetirizine; oral
2.9
9.0
82
451
A02BC02
ATC
pantoprazole; systemic
3.7
9.0
119
804
P01BA02
ATC
hydroxychloroquine; oral
4.6
8.9
23
57
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.0
8.9
28
81
H02AB09
ATC
hydrocortisone; systemic
12.7
8.8
15
13
L95.9
ICD-10 Finland
Vasculitis limited to skin, unspecified
53.3
8.8
10
*
L01AA01
ATC
cyclophosphamide; systemic
53.3
8.8
10
*
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
5.2
8.6
19
41
DHA10
NOMESCO Finland
Biopsy of cavity of nose
21.6
8.6
12
6
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
10.4
8.5
16
17
B01AA03
ATC
warfarin; systemic
3.4
8.5
36
128
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.9
8.4
28
84
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
8.4
8
*
D69.0
ICD-10 Finland
Allergic purpura
35.5
8.2
10
*
R03AL09
ATC
formoterol, glycopyrronium bromide and beclometasone; inhalant
9.3
8.1
16
19
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
4.5
7.9
21
53
N06AX21
ATC
duloxetine; oral
3.4
7.8
32
111
DPA30
NOMESCO Finland
Sphenotomy
19.7
7.7
11
6
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
10.9
7.7
14
14
R06.0
ICD-10 Finland
Dyspnoea
2.8
7.7
53
248
R01AD09
ATC
mometasone; nasal
2.7
7.6
87
522
ZXA10
NOMESCO Finland
Bilateral
3.0
7.6
40
161
R03DC01
ATC
zafirlukast; oral
14.4
7.5
12
9
R03AK11
ATC
formoterol and fluticasone; inhalant
11.8
7.5
13
12
M31.0
ICD-10 Finland
Hypersensitivity angiitis
+∞
7.3
7
*
M30.8
ICD-10 Finland
Other conditions related to polyarteritis nodosa
+∞
7.3
7
*
J01MA02
ATC
ciprofloxacin; systemic
2.6
7.2
69
377
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.7
7.2
25
77
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
6.3
7.0
18
32
J47
ICD-10 Finland
Bronchiectasis
10.1
6.9
13
14
J31.0
ICD-10 Finland
Chronic rhinitis
3.7
6.9
24
74
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.6
6.7
50
241
R06AX26
ATC
fexofenadine; oral
4.1
6.6
19
51
UKC02
NOMESCO Finland
Cystoscopy
3.3
6.5
28
99
G58.7
ICD-10 Finland
Mononeuritis multiplex
72.9
6.5
7
*
WX105
NOMESCO Finland
Surface analgesia on skin or mucosa
3.7
6.4
22
67
TPH04
NOMESCO Finland
Cathetrisation of vein
2.7
6.4
42
189
4939X
ICD-9 Finland
Asthma, unspecified[ASTHMA BRONCHIALE NUD]
19.0
6.3
9
5
SPAT1262
SPAT
Handing over of treatment supplies
3.0
6.3
33
131
M81.4
ICD-10 Finland
Drug-induced osteoporosis
28.0
6.3
8
*
4460B
ICD-9 Finland
Polyarteritis nodosa and allied conditions, Polyarteritis nodosa[POLYARTERITIS NODOSA CUM INFILTRATIONE PULMONUM]
+∞
6.3
6
*
L95.0
ICD-10 Finland
Livedoid vasculitis
+∞
6.3
6
*
L01BA01
ATC
methotrexate; systemic
8.3
6.3
13
17
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
5.7
6.2
17
33
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.5
6.2
53
272
H65.3
ICD-10 Finland
Chronic mucoid otitis media
10.7
6.1
11
11
R01AD11
ATC
triamcinolone; nasal
3.7
6.1
21
64
N03AX16
ATC
[U] pregabalin
2.6
6.1
44
207
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.9
6.1
32
128
M13.9
ICD-10 Finland
Arthritis, unspecified
4.1
6.0
17
45
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
41
25
22.47
50.71
5.2
1.1
12.17
—
iu/ml
—
7
0
103
555
3.95
13.37
9.1
6.4
1.22
1.22
mmol/l
0.07
84
474
16
8
22.24
11.41
1.3
1.0
—
—
—
0
0
94
514
3.36
11.15
7.1
5.4
1.21
1.22
mmol/l
0.19
88
474
25
57
5.09
10.75
1.2
3.2
33.06
42.42
u/l
1.19
25
52
20
37
6.11
10.73
3.9
1.4
—
—
—
0
0
25
59
4.91
10.32
4.7
3.6
1.98
1.73
mmol/l
0.16
19
47
99
580
3.23
10.03
7.0
3.3
0.00
0.00
estimate
-0.00
37
98
19
21
10.23
9.88
5.8
2.7
5.08
5.48
e9/l
0.16
19
21
98
576
3.16
9.77
8.8
4.5
0.00
0.00
estimate
-0.00
38
100
97
567
3.15
9.77
7.1
3.3
0.00
0.00
estimate
-0.00
39
110
19
22
9.76
9.64
6.4
2.7
60.63
60.82
%
0.01
19
22
21
46
5.17
9.40
2.0
1.5
—
—
—
0
0
45
179
3.20
8.84
2.6
1.8
—
—
—
0
0
57
263
2.92
8.60
1.8
1.6
1.32
0.95
mg/l
0.50
47
207
87
505
2.81
8.42
6.1
4.0
33.66
36.24
g/l
3.77
80
477
73
409
2.58
7.27
7.1
2.8
—
—
—
0
0
18
31
6.47
7.19
3.2
2.1
—
—
—
0
0
58
296
2.60
6.95
8.0
3.6
0.00
0.00
estimate
-0.00
37
103
63
335
2.56
6.93
6.7
3.7
11.97
6.16
mg/mmol
0.48
46
199
77
450
2.52
6.92
6.4
3.7
36.83
30.27
ng/l
0.24
63
287
15
21
7.83
6.91
7.6
8.4
—
139.80
iu/ml
—
0
5
14
18
8.48
6.79
1.5
1.9
—
—
—
0
0
13
15
9.39
6.71
1.5
2.1
—
—
—
0
0
15
23
7.14
6.53
2.5
1.9
23.86
24.82
mmol/l
0.33
15
23
85
530
2.46
6.51
23.4
12.0
1.32
1.19
inr
0.65
28
147
20
57
3.91
6.42
1.6
1.3
—
—
—
0
0
16
39
4.49
6.27
2.7
1.5
—
—
—
0
0
12
15
8.61
5.97
1.6
1.9
—
—
—
0
0
23
77
3.36
5.84
2.4
1.6
—
—
—
0
0
73
446
2.28
5.60
7.4
3.3
—
—
—
0
0
12
17
7.59
5.56
1.6
1.9
—
—
—
0
0
13
21
6.68
5.53
1.3
1.2
—
—
—
0
0
14
26
5.84
5.38
3.3
1.8
—
—
—
0
0
56
313
2.29
5.24
6.9
2.7
0.32
0.56
e6/l
0.77
49
227
12
19
6.78
5.20
3.0
1.7
8.74
8.08
kpa
0.63
12
19
8
6
14.00
5.14
1.0
1.0
—
—
—
0
0
8
6
14.00
5.14
1.8
1.8
—
—
—
0
0
9
10
9.50
4.86
1.6
1.6
—
—
—
0
0
14
30
5.05
4.83
3.4
1.8
—
—
—
0
0
29
124
2.67
4.80
2.0
1.7
—
—
—
0
0
41
210
2.33
4.63
1.3
1.2
43.67
39.57
iu/ml
0.06
15
78
7
5
14.60
4.62
1.9
1.6
—
—
—
0
0
28
120
2.65
4.61
2.1
1.6
—
—
—
0
0
8
8
10.49
4.58
1.7
1.1
—
—
—
0
0
13
28
4.99
4.49
4.8
2.7
4.93
4.98
kpa
0.06
13
28
9
12
7.91
4.42
1.1
1.0
—
—
—
0
0
9
12
7.91
4.42
1.1
1.0
—
—
—
0
0
14
34
4.44
4.34
3.3
1.7
—
—
—
0
0
7
6
12.17
4.32
1.9
1.5
—
—
—
0
0
18
64
3.07
4.13
4.4
5.7
24.97
25.19
mmol/l
0.08
18
64
10
18
5.88
4.05
1.4
1.3
—
—
—
0
0
12
28
4.57
3.92
2.2
1.5
—
—
—
0
0
9
15
6.32
3.88
1.8
1.0
—
—
—
0
0
12
29
4.41
3.80
3.1
3.8
28.33
27.83
mg/l
—
7
23
6
5
12.43
3.79
1.2
3.0
—
—
—
0
0
25
112
2.49
3.74
6.3
3.6
—
—
—
0
0
10
21
5.03
3.63
1.3
1.2
—
—
—
0
0
7
9
8.10
3.60
1.9
2.3
—
—
—
0
0
7
9
8.10
3.60
1.1
1.0
—
—
—
0
0
7
9
8.10
3.60
1.0
1.0
—
—
—
0
0
6
6
10.36
3.53
5.2
2.3
—
—
—
0
0
6
6
10.36
3.53
5.2
2.3
—
—
—
0
0
6
6
10.36
3.53
5.2
2.3
—
—
—
0
0
51
313
1.97
3.52
2.5
2.5
338.16
8101.73
umol/l
2.05
45
277
10
22
4.80
3.50
1.9
1.1
—
—
—
0
0
11
27
4.32
3.47
1.3
1.3
—
—
—
0
0
9
19
4.98
3.29
1.4
1.3
—
—
—
0
0
8
15
5.58
3.24
1.9
1.5
—
—
—
0
0
7
11
6.62
3.22
1.0
1.0
—
—
—
0
0
7
11
6.62
3.22
1.9
1.5
—
—
—
0
0
32
173
2.09
3.09
4.6
2.7
5.04
3.27
e6/l
0.45
18
87
6
8
7.76
3.08
1.0
1.0
—
—
—
0
0
5
5
10.29
3.00
1.6
2.0
639.60
1239.60
u/ml
—
5
5
5
5
10.29
3.00
1.4
1.0
—
—
—
0
0
10
27
3.90
2.94
1.4
2.0
—
—
—
0
0
6
9
6.89
2.89
1.0
1.1
—
—
—
0
0
36
210
1.95
2.81
1.3
1.2
0.90
16.52
u/ml
—
10
82
23
113
2.23
2.80
1.6
2.3
0.24
0.23
g/l
0.24
23
102
6
10
6.20
2.72
5.2
1.8
—
—
—
0
0
6
10
6.20
2.72
5.2
1.8
—
—
—
0
0
5
7
7.34
2.57
1.2
1.1
—
—
—
0
0
8
21
3.97
2.50
1.9
1.6
—
—
—
0
0
5
8
6.42
2.39
1.6
1.3
—
—
—
0
0
73
548
1.67
2.38
3.2
2.4
—
—
—
0
0
24
129
2.03
2.34
5.1
6.8
103.37
103.95
mmol/l
0.31
24
129
36
223
1.82
2.32
1.7
3.2
2.45
2.44
mmol/l
0.10
31
198
6
13
4.76
2.29
5.2
2.2
—
—
—
0
0
6
13
4.76
2.29
1.3
1.0
—
—
—
0
0
31
184
1.87
2.28
4.8
2.5
0.31
1.36
e6/l
3.55
18
97
12
48
2.64
2.25
4.0
2.1
—
—
—
0
0
5
9
5.71
2.23
1.6
1.1
—
—
—
0
0
5
9
5.71
2.23
1.6
1.2
—
—
—
0
0
42
276
1.73
2.22
2.8
2.2
—
—
—
0
0
6
14
4.42
2.17
5.2
2.1
—
—
—
0
0
137
1264
2.52
2.12
27.3
14.7
3.89
3.96
mmol/l
3.12
137
1232
6
15
4.12
2.06
5.2
2.0
—
—
—
0
0
6
15
4.12
2.06
5.2
2.0
—
—
—
0
0
6
15
4.12
2.06
5.2
2.0
—
—
—
0
0
61
453
1.60
1.99
2.4
1.8
86.66
98.24
pmol/l
1.30
33
222
5
11
4.66
1.95
1.4
1.1
—
—
—
0
0
139
1300
2.67
1.90
33.8
15.2
80.78
73.99
umol/l
1.43
139
1300
8
28
2.96
1.89
3.9
1.6
—
—
—
0
0
108
927
1.65
1.84
5.2
4.2
15.08
14.67
pmol/l
0.95
103
850
15
74
2.15
1.82
2.6
3.9
98.53
175.27
ng/l
0.85
15
66
7
23
3.14
1.82
4.7
1.8
—
—
—
0
0
7
23
3.14
1.82
4.7
1.8
—
—
—
0
0
136
1260
2.28
1.77
27.2
14.6
139.66
139.81
mmol/l
0.31
136
1229
6
18
3.43
1.76
2.8
1.7
—
—
—
0
0
33
217
1.67
1.72
3.4
3.8
163.17
83.86
ng/l
0.42
23
163
10
42
2.48
1.65
8.1
4.3
25.35
25.32
mmol/l
—
10
42
8
32
2.59
1.62
1.0
1.1
—
—
—
0
0
21
125
1.80
1.54
4.1
6.9
5.02
5.22
kpa
0.55
21
117
5
15
3.41
1.53
4.8
1.8
—
—
—
0
0
32
217
1.61
1.48
1.6
1.4
—
—
—
0
0
7
28
2.57
1.47
1.1
1.4
—
—
—
0
0
5
16
3.20
1.45
1.6
1.2
—
—
—
0
0
5
16
3.20
1.45
4.8
1.8
—
—
—
0
0
5
16
3.20
1.45
4.8
1.8
—
—
—
0
0
5
16
3.20
1.45
4.8
1.8
—
—
—
0
0
5
16
3.20
1.45
4.8
1.8
—
—
—
0
0
5
16
3.20
1.45
4.8
1.8
—
—
—
0
0
21
128
1.75
1.43
4.0
6.9
1.65
1.71
mmol/l
0.03
21
103
10
48
2.16
1.31
6.4
2.9
45.66
47.64
%
—
10
48
12
63
1.99
1.27
2.2
1.5
—
—
—
0
0
28
192
1.57
1.24
1.7
1.6
1151.94
1203.41
nmol/l
0.10
23
156
122
1123
1.54
1.10
6.0
4.9
1.84
1.92
mu/l
0.34
115
1035
9
46
2.02
1.06
1.2
1.3
41.60
22.19
iu/l
—
9
38
9
47
1.97
1.04
3.7
2.4
1.36
1.51
%
—
9
47
127
1183
1.59
1.04
26.1
12.2
78.27
81.83
ml/min/173m2
1.06
119
969
7
35
2.05
1.01
1.6
1.3
—
—
—
0
0
5
23
2.21
0.99
1.6
1.9
—
—
—
0
0
123
1144
1.50
0.94
7.1
5.5
40.60
39.52
mmol/mol
0.64
117
1073
116
1068
1.43
0.93
35.1
15.5
14.73
14.97
%
0.24
116
1056
8
44
1.86
0.87
1.9
1.9
—
—
—
0
0
17
241
0.67
0.80
4.5
4.2
18.05
21.61
%
0.53
11
96
12
75
1.65
0.77
1.2
1.3
15.34
119.12
iu/ml
—
5
31
5
24
2.12
0.75
1.2
1.0
—
—
—
0
0
5
25
2.03
0.73
1.6
1.4
—
—
—
0
0
5
25
2.03
0.73
1.6
1.4
—
—
—
0
0
7
119
0.57
0.71
1.9
1.8
—
—
—
0
0
11
71
1.59
0.64
8.9
7.6
25.53
25.41
mmol/l
0.05
11
65
0
21
0.00
0.60
0.0
1.1
—
2.35
—
0
13
92
843
1.25
0.60
3.9
2.9
64.20
50.32
u/l
0.48
86
798
6
35
1.74
0.58
2.0
1.2
84.67
358.55
pmol/l
—
6
35
6
35
1.74
0.58
2.2
1.2
—
—
—
0
0
86
787
1.23
0.55
3.9
3.0
—
—
—
0
0
27
216
1.31
0.54
1.8
1.4
—
—
—
0
0
7
46
1.55
0.49
2.0
1.3
—
—
—
0
0
13
94
1.42
0.48
2.5
2.9
59.43
66.32
ml/min/173m2
—
7
37
139
1359
1.55
0.44
43.8
19.4
40.94
40.50
%
0.57
134
1299
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
7.03
—
0
19
9
71
1.29
0.37
1.4
1.3
—
—
—
0
0
27
228
1.23
0.37
1.5
1.7
440.68
472.19
pmol/l
0.37
22
199
6
43
1.41
0.35
1.7
1.1
—
—
—
0
0
6
43
1.41
0.35
1.7
1.1
—
—
—
0
0
139
1360
1.53
0.34
44.9
19.5
134.17
136.16
g/l
1.00
139
1341
10
130
0.75
0.31
11.5
8.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
189.45
—
0
12
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
7
58
1.22
0.18
1.0
1.0
—
—
—
0
0
122
1200
1.11
0.12
6.0
4.4
5.96
5.93
mmol/l
0.08
114
1119
11
99
1.12
0.06
2.0
1.7
—
—
—
0
0
12
110
1.10
0.05
2.2
1.9
—
—
—
0
0
15
144
1.05
0.00
5.2
4.1
33.73
33.04
%
0.09
15
96
0
9
0.00
-0.00
0.0
3.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
5
57
0.87
-0.00
1.2
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_CHURGSTRAUSS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_CHURGSTRAUSS | 1.776 [1.31, 2.4] | < 0.001 |
| Birth year | 0.997 [0.99, 1.01] | 0.509 |
During the follow-up period (1.1.1998 — 31.12.2019), 95 out of 338 females with M13_CHURGSTRAUSS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_CHURGSTRAUSS | 1.771 [1.23, 2.56] | 0.002 |
| Birth year | 0.988 [0.98, 1.0] | 0.009 |
During the follow-up period (1.1.1998 — 31.12.2019), 54 out of 192 males with M13_CHURGSTRAUSS died.
Mortality risk
Mortality risk for people of age
years, who have M13_CHURGSTRAUSS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.195% | 0.339% |
| 5 | 1.128% | 2.094% |
| 10 | 2.675% | 5.255% |
| 15 | 5.195% | 9.979% |
| 20 | 9.422% | 16.502% |
Relationships between endpoints
↥Index endpoint: M13_CHURGSTRAUSS – Polyarteritis with lung involvement [Churg-Strauss]/EGPA
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data